Xin Lang Cai Jing·2025-09-26 07:13Core Viewpoint - JianKai Technology experienced a 5.07% decline in stock price, closing at 93.45 CNY per share, with a total market capitalization of 5.668 billion CNY as of September 26 [1] Company Overview - JianKai Technology, established on October 9, 2001, and listed on August 26, 2020, is located in Haidian District, Beijing. The company specializes in the research, production, and sales of medical-grade polyethylene glycol and its active derivatives [1] - The revenue composition of JianKai Technology is as follows: 96.79% from product sales, 2.91% from technology licensing fees, and 0.30% from transportation services [1] Shareholder Information - CITIC JianKong Fund has a presence among the top ten circulating shareholders of JianKai Technology, with its CITIC JianKong Medical Reform A fund (002408) newly entering the list in the second quarter, holding 350,000 shares, which accounts for 0.58% of circulating shares [2] - The estimated floating loss for CITIC JianKong Medical Reform A today is approximately 1.7465 million CNY [2] Fund Manager Profile - The fund manager of CITIC JianKong Medical Reform A is Xie Wei, who has been in the position for 7 years and 116 days. The fund's total asset size is 1.987 billion CNY, with the best return during his tenure being 108.27% and the worst return being -19.3% [3]